Adlai Nortye (ANL) Invested Capital (2022 - 2026)
Adlai Nortye (ANL) posted quarterly Invested Capital of $26.7 million for Q4 2025, down 2.26% year-over-year from $27.4 million in Q4 2024, and down 39.3% quarter-over-quarter from $44.1 million in Q2 2025.
Analysis
Adlai Nortye (ANL) Invested Capital (2022 - 2026) Analysis & Trends
Adlai Nortye (ANL) has reported Invested Capital for 4 consecutive years, with $26.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Invested Capital fell 2.26% year-over-year to $26.7 million; the TTM figure through Dec 2025 stood at $137.0 million (down 65.29% YoY), while the FY2025 annual figure was $26.7 million, down 2.26% from the prior year.
- Invested Capital eased to $26.7 million in Q4 2025 per ANL's latest filing, from $44.1 million in the prior quarter.
- Across five years, Invested Capital topped out at $296.9 million in Q4 2022 and bottomed at $26.7 million in Q4 2025.
- Historically, Invested Capital has averaged $77.6 million across 4 years, with a median of $35.3 million in 2023.
- Annual changes were most pronounced in 2023 — Invested Capital plunged 89.34% — and 2025, when it gained 13.27%.
- Adlai Nortye's Invested Capital stood at $296.9 million in 2022, then slumped by 89.34% to $31.7 million in 2023, then slipped by 13.58% to $27.4 million in 2024, then decreased by 2.26% to $26.7 million in 2025.
- Business Quant data shows ANL's Invested Capital at $26.7 million in Q4 2025, $44.1 million in Q2 2025, and $27.4 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 33.70 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 7.35 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 6.25 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.13 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.30 Bn |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - | 239.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 239.79 Mn |
| Dec 31, 2025 | 16.26 Mn |
| Jun 30, 2025 | 51.97 Mn |
| Dec 31, 2024 | 26.33 Mn |
| Jun 30, 2024 | 92.26 Mn |
| Dec 31, 2023 | 135.76 Mn |
| Dec 31, 2022 | -232.68 Mn |